Gastrointestinal Impact and Tool Performance in Juvenile Systemic Sclerosis Using the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract, Version 2.0 Assessment
Authors' conclusion
The UCLA GIT 2.0 captures the frequency and severity of GI symptoms in patients with jSSc and demonstrates acceptable validity and sensitivity to change.
Study context
- Population
- Patients with juvenile-onset SSc from the National Registry for Childhood Onset Scleroderma who completed the UCLA GIT 2.0
- Participants
- 51 patients
- Outcome
- GI manifestations measured by UCLA GIT 2.0 patient-reported outcome (PRO) instrument; its validity and responsiveness
Methodological detailsNational Registry for Childhood Onset Scleroderma, Spearman correlations, paired assessments one year later
- National Registry for Childhood Onset Scleroderma
- Spearman correlations
- Paired assessments one year later
Performance
As reported in the abstract
UCLA GIT 2.0 total score
Mean UCLA GIT 2.0 total score (mild gastrointestinal (GI) burden)
0.30
Further findings
Responsiveness: change in mean total UCLA GIT 2.0 (22 patients with paired data) · one year later
- Mean total UCLA GIT 2.0 improved (points), P = 0.039
- 0.11
- Clinically important improvement in at least one domain
- 55%
- Preliminary responsiveness
Original publication
Gastrointestinal Impact and Tool Performance in Juvenile Systemic Sclerosis Using the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract, Version 2.0 Assessment. Arthritis Care Res (Hoboken). Published 11 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →